drugset / Trial / NCT05301660

Effect of Nicotine Transdermal Patch on Cognitive Function and Glycolipid Metabolism in Non-smoking Schizophrenia

NCT05301660

Phase 0 Unknown 80 enrolled Sir Run Run Shaw Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Schizophrenia is a group of severe mental disorders of unknown etiology, with significant abnormalities in mental activities such as cognition, thinking, emotion, and behavior, and lead to obvious occupational and social function damage. At present, many studies have found that nicotine and cognitive function changes are related, and many studies have carried out a series of explorations for patients with schizophrenia, but there is no study on the mechanism of nicotine on cognitive function in patients with schizophrenia through changes in glycolipid metabolism, and this study intends to explore whether nicotine participates in the cognitive changes of patients with schizophrenia by regulating glycolipid metabolism, which is conducive to the in-depth study of the mechanism of cognitive function change in schizophrenia, in order to find an effective way to improve the cognitive function of schizophrenia.

Timeline

Start
2022-03-22
Primary completion
2023-02-15
Completion
2023-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicotine Unknown 14 mg Other

Indications